These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 11422945)
21. Blood screening--the next generation in testing. Chappel RJ; Dax EM Aust N Z J Med; 1999 Dec; 29(6):763-4. PubMed ID: 10677118 [No Abstract] [Full Text] [Related]
22. Kill and cure. The hope and reality of virus inactivation. Prowse C Vox Sang; 1994; 67 Suppl 3():191-6. PubMed ID: 7975491 [No Abstract] [Full Text] [Related]
23. Dual reduction in the immunologic and infectious complications of transfusion by filtration/removal of leukocytes from donor blood soon after collection. Rawal BD; Davis RE; Busch MP; Vyas GN Transfus Med Rev; 1990 Oct; 4(4 Suppl 1):36-41. PubMed ID: 2134639 [No Abstract] [Full Text] [Related]
24. Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products. Goodrich RP; Doane S; Reddy HL Biologicals; 2010 Jan; 38(1):20-30. PubMed ID: 20093041 [TBL] [Abstract][Full Text] [Related]
25. The continuing risk of transfusion-transmitted infections. Blajchman MA; Vamvakas EC N Engl J Med; 2006 Sep; 355(13):1303-5. PubMed ID: 17005947 [No Abstract] [Full Text] [Related]
32. [Techniques of preparation and indications of labile blood products]. Clément S Transfus Clin Biol; 2011 Apr; 18(2):250-61. PubMed ID: 21474355 [TBL] [Abstract][Full Text] [Related]
33. West Nile virus. Katz LM; Bianco C N Engl J Med; 2003 Nov; 349(19):1873-4; author reply 1873-4. PubMed ID: 14602891 [No Abstract] [Full Text] [Related]
34. Approaches to the reduction of viral infectivity in cellular blood components and single donor plasma. Wagner SJ; Friedman LI; Dodd RY Transfus Med Rev; 1991 Jan; 5(1):18-32. PubMed ID: 1802274 [No Abstract] [Full Text] [Related]
35. Status of NAT screening for HCV, HIV and HBV--experiences of the German Red Cross Blood Donation Services. Seifried E; Findhammer S; Roth WK Dev Biol (Basel); 2002; 108():23-7. PubMed ID: 12220139 [No Abstract] [Full Text] [Related]
36. Blood safety and the choice of anti-hemophilic factor concentrate. Janco RL Pediatr Blood Cancer; 2007 Jan; 48(1):117. PubMed ID: 17063470 [No Abstract] [Full Text] [Related]
37. [Transfusion medicine in near future]. Sekiguchi S Rinsho Byori; 1992 Jun; 40(6):617-25. PubMed ID: 1513033 [No Abstract] [Full Text] [Related]
38. Virus safety of human blood, plasma, and derived products. Guertler L Thromb Res; 2002 Oct; 107 Suppl 1():S39-45. PubMed ID: 12379292 [TBL] [Abstract][Full Text] [Related]